Indivior’s Nasdaq-Only Shift Sparks Trading Surge and Goldman Sachs 7.8% Stake

Introduction

Indivior PLC (NASDAQ: INDV), headquartered in Slough, United Kingdom, is a specialty pharmaceutical company focused on the development and commercialization of medications for opioid use disorder (OUD). Founded in 2014 as a spin-off from Reckitt Benckiser, the company’s primary products—Sublocade, Subutex, and Suboxone—combine buprenorphine with naloxone or extended-release formulations to support recovery and reduce relapse.

Corporate Structure and Leadership

Indivior PLC is a public limited company incorporated on September 26, 2014, with its registered office at 234 Bath Road, Slough, SL1 4EE. The firm employs between 1,001 and 5,000 people worldwide and maintains a dual-listed structure: it transferred its primary share listing to the U.S. Nasdaq Global Select Market in May 2024 and delisted from the London Stock Exchange effective June 2025.

In January 2025, Dr. David Wheadon assumed the role of Board Chair. On February 1, 2025, Joe Ciaffoni was appointed Chief Executive Officer, succeeding Mark Crossley. Additionally, Vanessa Procter was named Executive Vice President of Corporate Affairs on July 23, 2025.

Opioid medications by Stephen Foster

Recent Developments and News

• On May 23, 2024, shareholders approved the switch of the primary listing to Nasdaq, with London becoming secondary.
• On June 30, 2025, Indivior completed its delisting from the London Stock Exchange.
• On July 25, 2025, the company was added to the U.S. Russell 2000® and Russell 3000® Indexes.
• On July 31, 2025, Indivior filed its quarterly report on Form 10-Q for the period ended June 30, 2025, detailing its second-quarter financial performance and reaffirming guidance for fiscal 2025.
• On August 4, 2025, an amendment to a June 20, 2025 Form 8-K (Item 5.02) updated disclosures concerning executive leadership changes.
• On August 13, 2025, The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC amended their Schedule 13G/A, reporting collective beneficial ownership of 9,789,169 shares, equal to 7.8% of Indivior’s outstanding stock.

Financial and Strategic Analysis

As of August 19, 2025, INDV shares closed at $23.42, unchanged on the day. Trading volume reached 174,422 shares versus an average daily volume of 81, representing a volume increase of approximately 9,999.99%. The increased trading activity reflects investor interest following index inclusion and corporate updates.

Indivior’s primary focus remains the opioid-use-disorder market, where it reports a significant product pipeline. The shift of its main listing to Nasdaq aligns with its U.S.-focused growth strategy and enhances access to U.S. institutional investors. Management changes, including the appointment of Joe Ciaffoni and Vanessa Procter, indicate an emphasis on commercial execution and stakeholder engagement. The amended Schedule 13G/A reflects institutional support and potential influence from The Goldman Sachs Group.

Market Position and Industry Context

Indivior operates within a regulated pharmaceutical sector characterized by ongoing opioid-related litigation and competition from generic alternatives. The company has faced legal resolutions totaling over $2 billion between 2019 and 2020 related to its Suboxone marketing practices. In response, Indivior has implemented compliance controls and focused on extended-release formulations. Its products compete with both branded and generic buprenorphine therapies, while pipeline candidates targeting substance-use disorders aim to differentiate on efficacy, safety, and diversion resistance. Factors such as regulatory oversight, patent expirations, and reimbursement dynamics will impact Indivior’s market position in the United States and over 30 other countries.

tl;dr

• On July 31, 2025, Indivior filed its Q2 2025 results and maintained fiscal 2025 guidance.
• On July 25, 2025, the company joined the Russell 2000® and 3000® Indexes.
• On June 30, 2025, Indivior completed its delisting from the London Stock Exchange, retaining Nasdaq as its primary market.
• On August 13, 2025, The Goldman Sachs Group reported a 7.8% stake via an amended Schedule 13G/A.
• Looking ahead to H2 2025, Indivior continues to focus on its opioid-use-disorder portfolio, index-driven institutional demand, and potential pipeline developments.